Phibro Animal Health (PAHC) and Prestige Consumer Healthcare (PBH) on Torvanta's measures: PAHC grades higher on 2 of the 4 factor families and PBH on 2.
| PAHC | PBH | |
|---|---|---|
| Value grade | B | A- |
| Growth grade | C+ | D+ |
| Profitability grade | C+ | B- |
| Momentum grade | C- | D+ |
| Market value | $1.6B | $2.3B |
| P/E (trailing) | 16.1x | 13.4x |
| Forward P/E (Torvanta model estimate) | Subscribers | Subscribers |
| Revenue, last 12 months | $1.5B | $1.1B |
| Revenue growth (y/y) | +17% | -1% |
| Operating margin | 12.8% | 26.3% |
| Return on invested capital | 13.3% | 6.0% |
| Free-cash-flow yield | 0.6% | 10.4% |
| Total return, 1 year | -4.2% | -23.3% |
| Total return, 3 years | n/a | n/a |
Full PAHC analysis · Full PBH analysis
Phibro Animal Health (PAHC) and Prestige Consumer Healthcare (PBH) on Torvanta's measures: PAHC grades higher on 2 of the 4 factor families and PBH on 2. Which fits an investor depends on their goals; this is research, not a recommendation. Subscribers see where the model ranks each and its expected return.
On trailing earnings PAHC trades at 16.1x and PBH at 13.4x; their value grades are B and A- against their sectors.
Subscribers get a rating, a fair value estimate, a 12-month target and a risk read for every S&P 500 company, Torvanta's earnings estimates, and three model portfolios (Active, Adaptive and Patient) with every trade sized and explained. A free account includes 3 full Stock Analyst reports a month.
See plans Or get the free weekly newsletterTorvanta is a research publisher, not a registered investment adviser or broker-dealer. It is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.
All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer
Data powered by Tiingo.com